EFFICACY AND SAFETY OF LONG TERM CYCLOPHOSPHAMIDE TREATMENT FOR INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS

被引：2
|
作者：
Kwon, H. M. [1 ]
Karig, E. H. [1 ]
Go, D. J. [1 ]
Park, J. K. [1 ]
Lee, E. Y. [1 ]
Song, Y. W. [1 ]
Lee, H. -J. [2 ]
Lee, E. B. [1 ]
机构：
[1] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea
[2] Seoul Natl Univ, Coll Med, Radiol, Seoul, South Korea
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷
关键词：
D O I：
10.1136/annrheumdis-2014-eular.4302
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0621
引用
收藏
页码：1011 / 1011
页数：1
相关论文
共 50 条
  • [1] LONG-TERM EFFECTIVENESS AND SAFETY OF CYCLOPHOSPHAMIDE IN SYSTEMIC SCLEROSIS LUNG DISEASE
    Chakr, R.
    Gasparin, A.
    Neves, M.
    Rangel, G.
    Hendler, J.
    Moro, A. L.
    Zanchet, D.
    Siqueira, I.
    Hax, V.
    Palominos, P.
    Bredemeier, M.
    Kohem, C.
    Brenol, C.
    Monticielo, O.
    Brenol, J. C. T.
    Xavier, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 565 - 566
  • [2] RITUXIMAB AND CYCLOPHOSPHAMIDE COMPARISON FOR EFFICACY AND SAFETY IN THE PATIENTS WITH SYSTEMIC SCLEROSIS ASSOCIATED WITH INTERSTITIAL LUNG DISEASE
    Koneva, Olga
    Ananyeva, Lidia P.
    Garzanova, Liudmila
    Desinova, Oxana
    Ovsyannikova, Olga
    Starovoytova, Mayya
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 169 - 169
  • [3] COMPARISON OF LONG-TERM CYCLOPHOSPHAMIDE (CY) AND MYCOPHENOLATE MOFETIL (MMF) EFFICACY AND SAFETY IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) AND INTERSTITIAL LUNG DISEASE (ILD)
    Koneva, O.
    Ovsyannikova, O.
    Desiniva, O.
    Garzanova, L.
    Ananieva, L.
    Starovoytova, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1108 - 1109
  • [4] Pulse therapy of cyclophosphamide in treatment of systemic sclerosis with interstitial lung disease
    Damjanov, N
    Palov, S
    Vukovic, I
    Todorovic, N
    Milenkovic, M
    Radunovic, G
    Rebic, P
    JOURNAL OF RHEUMATOLOGY, 2001, 28 : 58 - 58
  • [5] Interstitial lung disease associated with systemic sclerosis -: What is the evidence for efficacy of cyclophosphamide?
    Berezne, Alice
    Valeyre, Dominique
    Ranque, Brigitte
    Guillevina, Loic
    Mouthon, Luc
    AUTOIMMUNITY, PT B: NOVEL APPLICATIONS OF BASIC RESEARCH, 2007, 1110 : 271 - 284
  • [6] Efficacy of Rituximab Versus Cyclophosphamide and Mycophenolate for the Treatment of Interstitial Lung Disease in Systemic Sclerosis: A Systematic Review
    Parikh, Aneri
    Francis, Aida J.
    Sreenivasan, Chithra
    Pandey, Manorama
    AlQassab, Osamah
    Kanthajan, Tatchaya
    AlEdani, Esraa M.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (08)
  • [7] Intravenous (IV) cyclophosphamide for treatment of systemic sclerosis with interstitial lung disease.
    Kyndt, X
    Pasturel-Michon, U
    Hachulla, E
    Hatron, PY
    Rémy-Jardin, M
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S102 - S102
  • [8] Efficacy of Mycophenolate As a Maintenance Therapy Following the Administration of Cyclophosphamide in the Treatment of Interstitial Lung Disease Associated with Systemic Sclerosis
    Narvaez, Javier
    Borrell Panos, Helena
    Castellvi, Ivan
    Heredia, Sergi
    Millan, Milena
    Herrera, Susana
    Armengol, Eulalia
    Maria LLobet, Josep
    Miquel Nolla, Joan
    Molina, Maria
    Jose Alegre, Juan
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [9] COMPARISON OF THE EFFICACY AND SAFETY OF CYCLOPHOSPHAMIDE (SP) AND RITUXIMAB (RTM) IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) WITH INTERSTITIAL LUNG DISEASE (ILD)
    Koneva, O.
    Ananieva, L.
    Garzanova, L.
    Desinova, O.
    Ovsyannikova, O.
    Starovoytova, M.
    CHEST, 2020, 157 (06) : 373A - 373A
  • [10] Efficacy of Cyclophospamide in the Treatment of Interstitial Lung Disease Associated with Systemic Sclerosis
    Espinosa, Gerard
    Pilar Simeon, Carmen
    Plasin, Miguel Angel
    Xaubet, Antoni
    Munoz, Xavier
    Fonollosa, Vicent
    Cervera, Ricard
    Vilardell, Miguel
    ARCHIVOS DE BRONCONEUMOLOGIA, 2011, 47 (05): : 239 - 245
12345